1
|
Zhang XY, Han W, Lyu ZH, Zhao HY, Fu P, Zhao CJ. [Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:664-667. [PMID: 37400396 DOI: 10.3760/cma.j.cn501113-20230313-00110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Abstract
Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.
Collapse
Affiliation(s)
- X Y Zhang
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - W Han
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - Z H Lyu
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - H Y Zhao
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - P Fu
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| | - C J Zhao
- Department of Nuclear Medicine, The First Clinical Hospital Affiliated to Harbin Medical University, Harbin 150001, China
| |
Collapse
|
2
|
Liu ML, Zhang ZF, Fu P, Ye YF, Guo F, Wang Q, He JJ, Li XW, Yan YH, Liao XF, Zhou XP, Tuo ZH, Wang Z. [Chinese expert consensus on management of dyslipidemia in the elderly]. Zhonghua Nei Ke Za Zhi 2022; 61:1095-1118. [PMID: 36207965 DOI: 10.3760/cma.j.cn112138-20220407-11251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Dyslipidemia is an important risk factor of atherosclerotic cardiovascular disease (ASCVD). Statins delay the occurrence and development of ASCVD, and reduce the risk of cardiovascular events and death. Due to safety concerns, there exist insufficient use of lipid-lowering agents and a high withdrawal rate of the agents in the elderly. To promote the prevention and treatment of ASCVD, this expert consensus is issued and focuses on the management of dyslipidemia of Chinese elderly basing on the clinical evidence of the use of lipid-lowering drugs by the elderly, and the lipid management guidelines and expert consensus recommendations at home and abroad.
Collapse
Affiliation(s)
- M L Liu
- Department of Geriatrics, Peking University First Hospital, Beijing 100034, China
| | - Z F Zhang
- Department of Geriatrics, Peking University First Hospital, Beijing 100034, China
| | - P Fu
- Department of Geriatrics, Peking University First Hospital, Beijing 100034, China
| | - Y F Ye
- Department of Cardiology, Second Medical Center, PLA General Hospital, Beijing 100853, China
| | - F Guo
- Department of Geriatric Cardiology, Hebei General Hospital, Shijiazhuang 050051, China
| | - Q Wang
- Department of Cardiology, Beijing Hospital, Beijing 100005, China
| | - J J He
- Department of Cardiology, Beijing Hospital, Beijing 100005, China
| | - X W Li
- Fuwai Hospital, National Center for Cardiovascular Diseases,Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100037, China
| | - Y H Yan
- Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
| | - X F Liao
- Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| | - X P Zhou
- Department of Geriatrics, Sichuan Provincial People's Hospital, Chengdu 610072, China
| | - Z H Tuo
- Department of Geriatrics, Changhai Hospital, Shanghai 200433, China
| | - Zhaohui Wang
- Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
| |
Collapse
|
3
|
Zhao LH, Ma Q, Fu P, Mao CY. [Clinicopathological analysis of invasive stratified mucin-producing carcinoma of the uterine cervix]. Zhonghua Bing Li Xue Za Zhi 2022; 51:135-137. [PMID: 35152633 DOI: 10.3760/cma.j.cn112151-20210629-00470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- L H Zhao
- Department of Pathology, Daping Hospital, Army Medical University, Chongqing 400042, China
| | - Q Ma
- Department of Pathology, Daping Hospital, Army Medical University, Chongqing 400042, China
| | - P Fu
- Department of Pathology, Daping Hospital, Army Medical University, Chongqing 400042, China
| | - C Y Mao
- Department of Pathology, Daping Hospital, Army Medical University, Chongqing 400042, China
| |
Collapse
|
4
|
Schrenk D, Fahrer J, Allemang A, Fu P, Lin G, Mahony C, Mulder PPJ, Peijnenburg A, Pfuhler S, Rietjens IMCM, Sachse B, Steinhoff B, These A, Troutman J, Wiesner J. Novel Insights into Pyrrolizidine Alkaloid Toxicity and Implications for Risk Assessment: Occurrence, Genotoxicity, Toxicokinetics, Risk Assessment-A Workshop Report. Planta Med 2022; 88:98-117. [PMID: 34715696 DOI: 10.1055/a-1646-3618] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
This paper reports on the major contributions and results of the 2nd International Workshop of Pyrrolizidine Alkaloids held in September 2020 in Kaiserslautern, Germany. Pyrrolizidine alkaloids are among the most relevant plant toxins contaminating food, feed, and medicinal products of plant origin. Hundreds of PA congeners with widespread occurrence are known, and thousands of plants are assumed to contain PAs. Due to certain PAs' pronounced liver toxicity and carcinogenicity, their occurrence in food, feed, and phytomedicines has raised serious human health concerns. This is particularly true for herbal teas, certain food supplements, honey, and certain phytomedicinal drugs. Due to the limited availability of animal data, broader use of in vitro data appears warranted to improve the risk assessment of a large number of relevant, 1,2-unsaturated PAs. This is true, for example, for the derivation of both toxicokinetic and toxicodynamic data. These efforts aim to understand better the modes of action, uptake, metabolism, elimination, toxicity, and genotoxicity of PAs to enable a detailed dose-response analysis and ultimately quantify differing toxic potencies between relevant PAs. Accordingly, risk-limiting measures comprising production, marketing, and regulation of food, feed, and medicinal products are discussed.
Collapse
Affiliation(s)
- Dieter Schrenk
- Food Chemistry and Toxicology, Technical University of Kaiserslautern, Kaiserslautern, Germany
| | - Jörg Fahrer
- Food Chemistry and Toxicology, Technical University of Kaiserslautern, Kaiserslautern, Germany
| | | | - Peter Fu
- National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR, USA
| | - Ge Lin
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
| | - Catherine Mahony
- Procter & Gamble, Technical Centres Limited, Weybridge, Surrey, United Kingdom
| | - Patrick P J Mulder
- Wageningen Food Safety Research, Wageningen University & Research, Wageningen, the Netherlands
| | - Ad Peijnenburg
- Wageningen Food Safety Research, Wageningen University & Research, Wageningen, the Netherlands
| | | | | | - Benjamin Sachse
- German Federal Institute of Risk Assessment (BfR), Berlin, Germany
| | | | - Anja These
- German Federal Institute of Risk Assessment (BfR), Berlin, Germany
| | | | | |
Collapse
|
5
|
Xu J, Feng ZP, Peng HY, Fu P. Omega-3 polyunsaturated fatty acids alleviate adenine-induced chronic renal failure via regulating ROS production and TGF-β/SMAD pathway. Eur Rev Med Pharmacol Sci 2021; 25:6825. [PMID: 34859840 DOI: 10.26355/eurrev_202111_27221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The article "Omega-3 polyunsaturated fatty acids alleviate adenine-induced chronic renal failure via regulating ROS production and TGF-β/SMAD pathway", by J. Xu, Z.-P. Feng, H.-Y. Peng, P. Fu, published in Eur Rev Med Pharmacol Sci 2018; 22 (15): 5024-5032-DOI: 10.26355/eurrev_201808_15645-PMID: 30070341, has been retracted by the authors due to input errors which occurred in the experimental data. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/15645.
Collapse
Affiliation(s)
- J Xu
- Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China
| | | | | | | |
Collapse
|
6
|
Chen F, Yu H, Nong Y, Jing H, Han Y, Wu J, Zhou M, Zhou Z, Liu Y, Fu P, Jin J, Hsue V, Chang A, Kong F. Risk Factors for Radiation Induced Lymphopenia in Patients With Breast Cancer: Does Radiotherapy Technique Matter? Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
7
|
Gao JD, Song H, Fu P, Guo YX, Zhang HY, Qiu M. Effects of etomidate on cell apoptosis during myocardial ischemia-reperfusion. J BIOL REG HOMEOS AG 2021; 35:10. [PMID: 34350750 DOI: 10.23812/21-si1-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J D Gao
- Department of Pain, Yantaishan Hospital, Yantai, China
| | - H Song
- Emergency Department, Jinan Zhangqiu District Hospital of TCM, Jinan, China
| | - P Fu
- Department of Anesthesiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China
| | - Y X Guo
- Department of Respiratory, Jinan Zhangqiu District People's Hospital, Jinan, China
| | - H Y Zhang
- Department of Pediatrics, Jinan Zhangqiu District People's Hospital, Jinan, China
| | - M Qiu
- Department of Anesthesiology, Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan, China
| |
Collapse
|
8
|
Wu Y, Zhu J, Fu P, Tong W, Hong H, Chen M. Machine Learning for Predicting Risk of Drug-Induced Autoimmune Diseases by Structural Alerts and Daily Dose. Int J Environ Res Public Health 2021; 18:ijerph18137139. [PMID: 34281077 PMCID: PMC8296890 DOI: 10.3390/ijerph18137139] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 06/20/2021] [Accepted: 06/25/2021] [Indexed: 12/28/2022]
Abstract
An effective approach for assessing a drug’s potential to induce autoimmune diseases (ADs) is needed in drug development. Here, we aim to develop a workflow to examine the association between structural alerts and drugs-induced ADs to improve toxicological prescreening tools. Considering reactive metabolite (RM) formation as a well-documented mechanism for drug-induced ADs, we investigated whether the presence of certain RM-related structural alerts was predictive for the risk of drug-induced AD. We constructed a database containing 171 RM-related structural alerts, generated a dataset of 407 AD- and non-AD-associated drugs, and performed statistical analysis. The nitrogen-containing benzene substituent alerts were found to be significantly associated with the risk of drug-induced ADs (odds ratio = 2.95, p = 0.0036). Furthermore, we developed a machine-learning-based predictive model by using daily dose and nitrogen-containing benzene substituent alerts as the top inputs and achieved the predictive performance of area under curve (AUC) of 70%. Additionally, we confirmed the reactivity of the nitrogen-containing benzene substituent aniline and related metabolites using quantum chemistry analysis and explored the underlying mechanisms. These identified structural alerts could be helpful in identifying drug candidates that carry a potential risk of drug-induced ADs to improve their safety profiles.
Collapse
Affiliation(s)
- Yue Wu
- National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; (Y.W.); (J.Z.); (W.T.); (H.H.)
| | - Jieqiang Zhu
- National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; (Y.W.); (J.Z.); (W.T.); (H.H.)
| | - Peter Fu
- National Center for Toxicological Research, Division of Biochemical Toxicology, U.S. Food and Drug Administration, Jefferson, AR 72079, USA;
| | - Weida Tong
- National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; (Y.W.); (J.Z.); (W.T.); (H.H.)
| | - Huixiao Hong
- National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; (Y.W.); (J.Z.); (W.T.); (H.H.)
| | - Minjun Chen
- National Center for Toxicological Research, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, Jefferson, AR 72079, USA; (Y.W.); (J.Z.); (W.T.); (H.H.)
- Correspondence: ; Fax: +1-870-543-7865
| |
Collapse
|
9
|
Xia H, Sun H, He S, Zhao M, Huang W, Zhang Z, Xue Y, Fu P, Chen W. Absent Cortical Venous Filling Is Associated with Aggravated Brain Edema in Acute Ischemic Stroke. AJNR Am J Neuroradiol 2021; 42:1023-1029. [PMID: 33737267 DOI: 10.3174/ajnr.a7039] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 12/01/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND AND PURPOSE Predicting malignant cerebral edema can help identify patients who may benefit from appropriate evidence-based interventions. We investigated whether absent cortical venous filling is associated with more pronounced early brain edema, which leads to malignant cerebral edema. MATERIALS AND METHODS Patients with acute ischemic stroke caused by large-vessel occlusion in the MCA territory who presented between July 2017 and September 2019 to our hospital were included. Collateral filling was rated using the modified Tan scale on CTA, and good collaterals were defined as a score of 2-3. The Cortical Vein Opacification Score (COVES) was calculated, and absent cortical venous filling was defined as a score of 0. Early brain edema was determined using net water uptake on baseline CT images. Malignant cerebral edema was defined as a midline shift of ≥5 mm on follow-up imaging or a massive cerebral swelling leading to decompressive hemicraniectomy or death. Multivariate linear and logistic regression models were performed to analyze data. RESULTS A total of 163 patients were included. Net water uptake was significantly higher in patients with absent than in those with favorable cortical venous filling (8.1% versus 4.2%; P < .001). In the multivariable regression analysis, absent cortical venous filling (β = 2.04; 95% CI, 0.75-3.32; P = .002) was significantly and independently associated with higher net water uptake. Absent cortical venous filling (OR, 14.68; 95% CI, 4.03-53.45; P < .001) and higher net water uptake (OR, 1.29; 95% CI, 1.05-1.58; P = .016) were significantly associated with increased likelihood of malignant cerebral edema. CONCLUSIONS Patients with absent cortical venous filling were associated with an increased early brain edema and a higher risk of malignant cerebral edema. These patients may be targeted for optimized adjuvant antiedematous treatment.
Collapse
Affiliation(s)
- H Xia
- From the Department of Radiology (H.X.), Shaoxing People's Hospital (Shaoxing Hospital, Zhejiang University School of Medicine), Shaoxing, Zhejiang, China
| | - H Sun
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - S He
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - M Zhao
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - W Huang
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Z Zhang
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Y Xue
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - P Fu
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - W Chen
- Department of Radiology (H.S., S.H., M.Z., W.H., Z.Z., Y.X., P.F., W.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| |
Collapse
|
10
|
Win TT, Bo B, Malec P, Fu P. The effect of a consortium of Penicillium sp. and Bacillus spp. in suppressing banana fungal diseases caused by Fusarium sp. and Alternaria sp. J Appl Microbiol 2021; 131:1890-1908. [PMID: 33694313 DOI: 10.1111/jam.15067] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Revised: 02/12/2021] [Accepted: 02/28/2021] [Indexed: 12/19/2022]
Abstract
AIMS This study sought to utilize indigenous soil micro-organisms to suppress wilt-causing fungal pathogens of the banana. METHODS AND RESULTS Fungal pathogens were isolated from wilt-affected rhizospheric soil, and potential antagonistic bacterial strains were isolated from healthy rhizospheric soil in the same area from which fungal pathogens were isolated. The antifungal activity of isolated micro-organisms against fungal pathogens was studied both in vitro and in vivo against fungal pathogens. It was found that Fusarium oxysporum and Alternaria sp. were pathogenic, while Penicillium sp., Bacillus velezensis and Bacillus subtilis were antagonistic. Moreover, it was seen that B. velezensis, B. subtilis and Penicillium sp. inhibited the growth of the two fungal pathogens in both in vitro and in vivo experiments. Further investigation indicated that B. velezensis, B. subtilis and Penicillium sp. were able to produce enzymatic antifungal compounds (chitinase and β-1,3-glucanase). The spray application around rhizome revealed that a combination of Bacillus spp. and Penicillium sp. in greenhouse conditions gave the highest reduction in disease severity by up to 60% to both fungal pathogens among the treatments. CONCLUSIONS Banana disease is seen to be induced not only by F. oxysporum but also by Alternaria sp. The isolated indigenous micro-organisms can effectively control both the pathogens. The combination of isolated antagonistic micro-organisms has thus demonstrated substantial potential for suppressing banana disease. SIGNIFICANCE AND IMPACT OF THE STUDY An antagonistic consortium isolated in this study has demonstrated remarkable potential for controlling fungal diseases caused by Fusarium sp. and Alternaria sp. Therefore, the use of indigenous microflora to improve disease suppression of banana plants against soil-borne pathogens is a preferable approach.
Collapse
Affiliation(s)
- T T Win
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China.,Biotechnology Research Department, Ministry of Education, Kyaukse, 05151, Myanmar
| | - B Bo
- Biotechnology Research Department, Ministry of Education, Kyaukse, 05151, Myanmar
| | - P Malec
- Department of Plant Physiology and Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
| | - P Fu
- State Key Laboratory of Marine Resource Utilization in South China Sea, Hainan University, Haikou, China
| |
Collapse
|
11
|
Jain P, Barrera C, Osme A, Toro P, Chahar S, Butler K, Khorrami M, Fu P, Corredor G, Bera K, Dowlati A, Madabhushi A. P68.02 Computer Extracted Morphology Features of Tumor Nuclei Predict Response to Chemotherapy and Prognostic of OS in Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Jain P, Khorrami M, Gupta A, Rajiah P, Bera K, Vaidya P, Fu P, Dowlati A, Madabhushi A. MA13.02 Novel Non-Invasive Radiomic Signatures Extracted from Radiographic Images can Predict Response to Systemic Treatment in Small Cell Lung Cancer. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Vaidya P, Bera K, Patil P, Gupta A, Fu P, Velu P, Choi H, Velcheti V, Madabhushi A. MA03.04 A Gender-Specific Radiomics Models for Predicting Recurrence in Early Stage (Stage I, II) Non-Small Cell Lung Cancer (ES-NSCLC) Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
14
|
Li JP, Yan R, Ma PL, Fu P, Tian HT, Wang LL. Effects of luteolin in different doses on the cardiomyocyte apoptosis in rats with myocardial ischemia reperfusion. J BIOL REG HOMEOS AG 2021; 34:2311-2315. [PMID: 33325211 DOI: 10.23812/20-560-l] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J P Li
- Department of Anesthesiology, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Qingdao, China
| | - R Yan
- ECG Room, Yantaishan Hospital, Yantai, China
| | - P L Ma
- Department of Anesthesiology, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital, Qingdao, China
| | - P Fu
- Department of Anesthesiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China
| | - H T Tian
- Department of Anesthesiology, Jining NO.1 People's Hospital, Affiliated Jining NO.1 People's Hospital of Jining Medical University, Jining Medical University, Jining, China
| | - L L Wang
- Department of Anesthesiology, Jining NO.1 People's Hospital, Affiliated Jining NO.1 People's Hospital of Jining Medical University, Jining Medical University, Jining, China
| |
Collapse
|
15
|
Li HX, Zhao JL, Liu L, Li Y, Yin LZ, Fu P, Li HF. Protective effect of sufentanil on skeletal muscle wasting in patients with sepsis. J BIOL REG HOMEOS AG 2021; 34:2127-2130. [PMID: 33191712 DOI: 10.23812/20-349-l] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- H X Li
- Department of Anesthesiology, The People's Hospital of Zhangqiu, Jinan, China
| | - J L Zhao
- Department of Anesthesiology, Zhangqiu Maternity and Child Care Hospital, Jinan, China
| | - L Liu
- EEG Room, The People's Hospital of Zhangqiu, Jinan, China
| | - Y Li
- Interventional Vascular Department, The People's Hospital of Zhangqiu, Jinan, China
| | - L Z Yin
- Health Management Center, The People's Hospital of Zhangqiu, Jinan, China
| | - P Fu
- Department of Anesthesiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China
| | - H F Li
- Department of Anesthesiology, The Third People's Hospital of Qingdao, Qingdao, China
| |
Collapse
|
16
|
ZHAO Y, Yang L, Fu P, Cui T. SUN-262 THE DIAGNOSTIC VALUE OF MULTI-DETECTOR CT ANGIOGRAPHY FOR CATHETER-RELATED CENTRAL VENOUS STENOSIS IN HEMODIALYSIS PATIENTS. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
17
|
ZHAO Y, Yang L, Salerno S, Li Y, Fu P. SUN-261 BLOOD PRESSURE VARIABILITY AND PROGNOSIS IN HEMODIALYSIS PATIENTS: A SYSTEMIC REVIEW AND META-ANALYSIS. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
18
|
Xu J, Feng ZP, Peng HY, Fu P. Omega-3 polyunsaturated fatty acids alleviate adenine-induced chronic renal failure via regulating ROS production and TGF-β/SMAD pathway. Eur Rev Med Pharmacol Sci 2019; 22:5024-5032. [PMID: 30070341 DOI: 10.26355/eurrev_201808_15645] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE To explore the role of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in adenine-induced rat chronic renal failure and its underlying mechanism. MATERIALS AND METHODS 30 Sprague Dawley (SD) rats were randomly assigned into three groups, namely sham group, adenine induction group (adenine group) and adenine induction + ω-3 PUFAs treatment group (ω-3 PUFAs group), with 10 rats in each group. Serum and kidney samples were collected after rats were sacrificed. Serum levels of Cr (creatinine) and BUN (urea nitrogen) were detected using commercial kits. HE (hematoxylin and eosin) staining was performed to evaluate the pathological changes of kidneys. Levels of oxidative stress indicators in rat kidney homogenate were detected by relative commercial kits, including SOD (superoxide dismutase), GSH (reduced glutathione), CAT (catalase), and T-AOC (total antioxidant capacity). Reactive oxygen species (ROS) production was also detected by immunofluorescence. Protein expressions of nuclear factor E2 related factor 2 (Nrf2) and transforming growth factor-beta (TGF-β)/SMAD pathway-related genes were detected by Western blot. RESULTS Serum levels of Cr and BUN in ω-3 PUFAs group were remarkably decreased compared with those of adenine group. Higher contents of SOD, GSH, CAT and T-AOC were observed in ω-3 PUFAs group compared with those of adenine group. Besides, MAD content and ROS production were lower in ω-3 PUFAs group than those of adenine group. Pathological changes of kidneys were alleviated after ω-3 PUFAs treatment. Western blot results demonstrated that ω-3 PUFAs treatment remarkably upregulates Nrf2, HO-1, NQO1, but downregulates relative genes in TGF-β/SMAD pathway. CONCLUSIONS ω-3 PUFAs alleviated adenine-induced chronic renal failure through enhancing antioxidant stress and inhibiting inflammatory response via regulating Nrf2 and TGF-β/SMAD pathway.
Collapse
Affiliation(s)
- J Xu
- Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China.
| | | | | | | |
Collapse
|
19
|
Yu Y, Wang L, Fu P, Cao S, Wang W, Machtay M, Yu J, Kong F. P2.12-03 Building and Validating a Lymphocyte Nadir Based Model to Predict Survival in Patients with Limited Stage-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1748] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Bera K, Vaidya P, Velu P, Choi H, Fu P, Gupta A, Velcheti V, Madabhushi A. P2.17-34 Integrated Clinico-Radiomic Nomogram for Predicting Disease-Free Survival (DFS) in Stage I and II Non-Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
21
|
Patil P, Khorrami M, Zagouras A, Bera K, Fu P, Gupta A, Velcheti V, Pennell N, Madabhushi A. P2.04-16 Novel CT Based Radiomic Features are Prognostic and Predictive of Benefit of Chemoimmunotherapy in Advanced Non-Squamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Velcheti V, Lu C, Bera K, Wang X, Fu P, Yang M, Rimm D, Schalper K, Madabhushi A. MA15.05 Computerized Measurements of Cellular Diversity on H&E Tissue Are Prognostic of OS and Associated with Mutational Status in NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Alilou M, Patil P, Fu P, Bera K, Velcheti V, Madabhushi A, Vaidya P. P1.04-25 CT Based Vessel Tortuosity Features Are Prognostic of Overall Survival and Predictive of Immunotherapy Response in NSCLC Patients. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Yu Y, Wang L, Cao S, Fu P, Jin J, Machtay M, Yu J, Kong F. Risk Factors Associated with Lymphocyte Reduction during Radiotherapy in Patients with Limited Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Yu Y, Wang L, Cao S, Fu P, Machtay M, Kong F, Yu J. Radiation Induced Lymphopenia and Overall Survival in Patients with Limited Stage Small Cell Lung Cancer Receiving Definitive Chemoradiation. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Fu P, Wang S, Yao M, Xiang A, Li J, Wang H, Geng C, Jin F, Yin Y, Huang X, Jiang Z. Abstract P4-14-14: Clinicopathological features and endocrine therapy mode of ER low expression (1%-9%) breast cancer patients in China. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-14-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Since 2010, ASCO/CAP recommended that ER be considered positive if ≥1% tumor cells with positive nuclear staining by immunohistochemistry (IHC) in breast cancer. ASCO/CAP also recommended considering endocrine therapy (ET) in ER positive patients. However, most breast cancers are either ER negative or ER strongly positive (≥10%), and tumors with low ER (1-9%) expression are rare. Up to now, the effect of ET is controversial for these patients with ER 1-9% and unfortunately, we know little about the clinical information of this subgroup. In this study, we analyzed the clinicopathological characteristics and ET mode of patients with low ER expression. We sought to figure out whether the ASCO/CAP guidelines affect clinical ET decision in China and Which features are important considerations for doctors to choose ET. We also evaluated the efficacy of ET in these patients. Methods: Patients diagnosed stage I-III primary invasive breast cancer with ER low expression (1-9%) between January 2008 and December 2016 were retrospectively identified from six hospitals in China. Result: 457 patients (2.7%) had low expression of ER (1-9%) of 17216 patients. Mean age at diagnosis was 49 years. 288 patients (49.9%)were younger than 50 years old. 254 patients (55.6%) had stage II disease and 37 patients (8.1%) had lymphovascular invasion (LVI). 260 patients (56.9%) were HER2 positive; 408 patients had PR negative or low expression; 327 patients' (71.6%) Ki-67 status were > 20%. 388 patients (85%) received chemotherapy. Of those 388 patients, 90% patients received anthracycline combined with taxol chemotherapy regimens. 170 patients (37.2%)received ET. Before 2010, only 25.7% patients with low ER expression received ET. The proportion of ET increased after the 2010 ASCO/CAP guideline was published. In 2013, 50% patients received ET. The rate of ET was totally different in six hospitals. 55% patients received ET in the hospital with highest rate, while only 4% patients received ET in the hospital with lowest rate. Using the univariate logistic regression analysis of ET, ER expression, PR expression, Ki-67 status and LVI were associated with the rate of ET. But after adjustment for other covariates, only ER level was significantly associated with the rate of ET. Compared to patients with ER<5% tumors, patients with ER≥5% tumors had a significantly higher probability of ET rate (OR, 2.882; 95% CI: 1.928-4.308; P < 0.001). Median follow time was 30 months. The 5-year RFS rate was 85%. Younger age and positive lymph nodes were associated with worse RFS. Survival rate did not differ significantly between patients with or without ET (without ER vs with ET: OR, 0.870; 95% CI: 0.508-1.448; p=0.61). Conclusions: 2010 ACSO/CAP recommendation indeed result in an increase of ET rate for patients with 1%-9% ER positive. But these patients do not appear to benefit from ET. Prospective studies are needed for these patients and we need more accurate way to evaluate ER levels, which associate with endocrine response.
Citation Format: Fu P, Wang S, Yao M, Xiang A, Li J, Wang H, Geng C, Jin F, Yin Y, Huang X, Jiang Z. Clinicopathological features and endocrine therapy mode of ER low expression (1%-9%) breast cancer patients in China [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-14-14.
Collapse
Affiliation(s)
- P Fu
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - S Wang
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - M Yao
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - A Xiang
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - J Li
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - H Wang
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - C Geng
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - F Jin
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - Y Yin
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - X Huang
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| | - Z Jiang
- The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China; The 307th Hospital of Chinese People's Liberation Army, Beijing, China; The Affiliated Hospital of Qingdao University, Qingdao, China; Hebei Medical University Fourth Affiliated Hospital, Shijiazhuang, China; The First Hospital of China Medical University, Shenyang, China; Jiangsu Province Hospital, Nanjing, China; Hangzhou First People' Hospital, Hangzhou, China; Hangzhou Normal University, Hangzhou, China
| |
Collapse
|
27
|
Yu DM, Fu P, Yu WT, Guo HJ, Yang XG, Zhao WH, Zhao LY. [Mean blood pressure among the adults in China 2010-2012: based on the results of mercury sphygmomanometer and converted electronic sphygmomanometer]. Zhonghua Yu Fang Yi Xue Za Zhi 2019; 51:933-938. [PMID: 29036997 DOI: 10.3760/cma.j.issn.0253-9624.2017.10.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the average systolic blood pressure (SBP) and diastolic blood pressure (DBP) among adults aged 18 years old and above in China between 2010 and 2012; and to compare the difference in the results measured by mercury sphygmomanometer and converted electronic sphygmomanometer. Methods: The data was collected from Chinese Nutrition and Health Surveillance in 2010-2012. 120 428 adults aged 18 years old and above were selected from 150 survey counties (districts) of 31 provinces in China Mainland, by multi-stage stratified and probability proportion to size (PPS) cluster randomization sampling method. The average blood pressure value was calculated from three systolic and diastolic blood pressure readings measured by mercury sphygmomanometer. The value of Electronic Sphygmomanometer was converted by regression formula. Age-standardized results were calculated incorporating a complex sample weighting using the population data from the National Bureau of Statistics in 2009. Results: The overall adjusted mean of SBP based on the value of mercury sphygmomanometer among Chinese adults aged 18 years old and above was 122 mmHg (1 mmHg=0.133 kPa), 124 mmHg in men and 120 mmHg in women. The average SBP value was separately 115, 127, and 137 mmHg in groups of adults aging 18-44, 45-59 and ≥60 years old. The average SBP was 122 mmHg in urban and 122 mmHg in rural areas. Mean DBP was 78 mmHg, 79 mmHg in men and 76 mmHg in women. The average DBP was separately 75, 81, and 81 mmHg in groups of adults aging 18-44, 45-59 and ≥60 years old. The average DBP was 78 mmHg in urban and 77 mmHg in rural areas. The overall adjusted mean of SBP based on converted electronic device was 129 mmHg,130 mmHg in men and 127 mmHg in women, respectively. The mean of SBP was separately122, 134, and 143 mmHg in groups of adults aging 18-44, 45-59 and ≥60 years old. Mean SBP was both 129 mmHg in urban and in rural areas. Mean DBP was 76 mmHg, 78 mmHg in men and 75 mmHg in women, respectively. The average DBP was separately 74, 79, and 79 mmHg in groups of adults aging 18-44, 45-59 and ≥60 years old. The average DBP was both 76 mmHg in urban and rural areas. Conclusion: The average SBP and DBP was different between the mercury sphygmomanometer and converted electronic device. However, the results from both measures showed that the blood pressure was higher in men than in women, the blood pressure increased with the increase of age, and there was no difference between urban and rural areas.
Collapse
Affiliation(s)
- D M Yu
- National Institute for Nutrition and Food Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | | | | | | | | | | | | |
Collapse
|
28
|
Vaidya P, Bera K, Fu P, Ganesan S, Khunger A, Patil P, Velcheti V, Madabhushi A. P3.16-10 Radiomic Features on CT are Prognostic of Recurrence as well as Predictive of Added Benefit of Adjuvant Chemotherapy in ES-NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
29
|
Hoimes C, Albany C, Hoffman-Censits J, Fleming M, Trabulsi E, Picus J, Cary C, Koch M, Walling R, Kelly W, Godwin J, Cooney M, Fu P, Nelson A, Patel K, Eitman C, Breen T, Neal A, Kaimakliotis H. A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.039] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Kasozi R, Choudhary A, Andrus K, Wong R, Randall R, Orovets C, Bali G, Karapetyan L, Gibson M, Fu P, Sloan J. Use of Percutaneous Endoscopic Gastrostomy Tube Feeding Support in Head and Neck Cancer Patients. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
31
|
Xia Q, He X, Lin G, Fu P. 1‐Formyl‐7‐hydroxy‐6,7‐dihydro‐5
H
‐pyrrolizine (9‐CHO‐DHP) ‐ A Biologically Proximate Pyrrolic Metabolite of Carcinogenic Pyrrolizidine Alkaloids. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.811.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Qingsu Xia
- Biochemical ToxicologyNational Center for Toxicological ResearchFDAJeffersonAR
| | - Xiaobo He
- Biochemical ToxicologyNational Center for Toxicological ResearchFDAJeffersonAR
| | - Ge Lin
- School of Biomedical SienceThe Chinese University of Hong KongSHATINHong Kong
| | - Peter Fu
- Biochemical ToxicologyNational Center for Toxicological ResearchFDAJeffersonAR
| |
Collapse
|
32
|
Jiang Z, Xu F, Fu P, Fan Z, Jin F, Liu H, Wang X, Zhang H, Wang H, Zhang J. Abstract P3-03-04: Not presented. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-03-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- Z Jiang
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - F Xu
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - P Fu
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - Z Fan
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - F Jin
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - H Liu
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - X Wang
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - H Zhang
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - H Wang
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| | - J Zhang
- Affiliated Hospital of Academy of Military Medical Sciences; The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Jilin University; The First Affiliated Hospital of China Medical University; Tianjin Medical University Cancer Institute and Hospital; Zhejiang Cancer Hospital; Dalian Central Hospital; Affiliated Hospital of Qingdao University; Second Affiliated Hospital of Harbin Medical University
| |
Collapse
|
33
|
Bai L, Li WW, Han HH, Liu JK, Fu P, Zhang XL, Guo YC. [Surveillance of contamination level and antimicrobial resistance analysis of Salmonella on broiler carcasses after chilling in 4 poultry slaughterhouses of Henan Province]. Zhonghua Yu Fang Yi Xue Za Zhi 2018; 52:124-128. [PMID: 29429264 DOI: 10.3760/cma.j.issn.0253-9624.2018.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: Tests were carried out for obtaining contamination level and antimicrobial resistance of Salmonella on broiler carcasses after chilling in four poultry slaughterhouses in Henan. Methods: Totally, two hundred sixty nine broiler carcasses after chilling were collected in four slaughterhouses with the daily slaughter amount around 15 000 to 50 000. For qualitative analysis of Salmonella EFSA method was used and for quantitative analysis of Salmonella modified Rappaport-Vassiliadis most probable number (MSRV-MPN) method was used. All of the isolates were subjected to antimicrobial susceptibility testing of 8 antibiotics by minimum inhibitory concentration (MIC). Results: Overall, 48.7% (131/269) of the broiler carcasses after chilling were contaminated by Salmonella, and the average of contamination level is 1.32 most probable number MPN/g. Eight serotypes were detected. The dominant serotype is Salmonella enteritidis (93, 71.0%) followed by Salmonella Indiana (21, 16.0%). Only 2 (1.5%) Salmonella enteritidis strains were sensitive to all the tested antibiotics and the remaining 129 isolates were resistant to at least one kind of eight class antibiotics. Among them, resistant to NAL was the common (104, 79.4%) and 51 (38.9%) Salmonella isolates were multidrug-resistant. Conclusion: The contamination rate and multiple antimicrobial resistant of Salmonella on broiler carcasses after chilling from slaughterhouses was very serious, while the isolates contained various serotypes.
Collapse
Affiliation(s)
- L Bai
- Key Laboratory of Food Safety Risk Assessment of Health, China National Center for Food Safety Risk Assessment, Beijing 100021, China
| | | | | | | | | | | | | |
Collapse
|
34
|
He X, Fu P, Aker WG, Hwang HM. Toxicity of engineered nanomaterials mediated by nano-bio-eco interactions. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2018; 36:21-42. [PMID: 29297743 DOI: 10.1080/10590501.2017.1418793] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Engineered nanomaterials may adversely impact human health and environmental safety by nano-bio-eco interactions not fully understood. Their interaction with biotic and abiotic environments are varied and complicated, ranging from individual species to entire ecosystems. Their behavior, transport, fate, and toxicological profiles in these interactions, addressed in a pioneering study, are subsequently seldom reported. Biological, chemical, and physical dimension properties, the so-called multidimensional characterization, determine interactions. Intermediate species generated in the dynamic process of nanomaterial transformation increase the complexity of assessing nanotoxicity. We review recent progress in understanding these interactions, discuss the challenges of the study, and suggest future research directions.
Collapse
Affiliation(s)
- Xiaojia He
- a Department of Marine Sciences , The University of Georgia , Athens , GA , USA
| | - Peter Fu
- b National Center for Toxicological Research , U.S. Food and Drug Administration , Jefferson , AR , USA
| | - Winfred G Aker
- c Department of Biology , Jackson State University , Jackson , MS , USA
| | - Huey-Min Hwang
- c Department of Biology , Jackson State University , Jackson , MS , USA
| |
Collapse
|
35
|
Cheng L, Gou S, Qiu H, Ma L, Fu P. Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol 2018; 191:116-124. [PMID: 28940198 PMCID: PMC5721235 DOI: 10.1111/cei.13051] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/19/2017] [Indexed: 02/05/2023] Open
Abstract
The complement system activation is involved in the development of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). The study aimed to investigate the expression of complement regulatory proteins (CRPs) CD46, CD55 and CD59 in kidneys of 51 AVV patients. The expression of CD46, CD55 and CD59 in kidneys was detected by immunohistochemistry and double immunofluorescence staining. The immunohistochemical examination revealed that expression of the three CRPs could be detected in the glomeruli and tubules of both AAV patients and normal controls. The expression levels of the three CRPs in glomeruli of patients with AAV were significantly lower than those of normal controls. The scores of CD46 and CD55 expression in the tubules of AAV patients were significantly lower than those of normal controls, while there was no significant difference between the scores of CD59 expression in tubules of AAV patients and those of normal controls. Among AAV patients, the expression level of CD46 in glomeruli correlated inversely with the proportion of normal glomeruli, while it correlated with tubular atrophy in renal interstitium (r = -0·305, P = 0·026; r = 0·330, P = 0·023, respectively). The expression levels of CD55 and CD59 in glomeruli correlated with the proportion of total crescents (r = 0·384, P = 0·006; r = 0·351, P = 0·011, respectively). Double immunofluorescence staining indicated that all three CRPs were expressed on endothelial cells, podocytes and mesangial cells in glomeruli. The expression levels of the three CRPs were dysregulated in kidneys of patients with AAV. The expression levels of CD46, CD55 and CD59 were associated with the severity of renal injury of AAV patients.
Collapse
Affiliation(s)
- L. Cheng
- Division of NephrologyKidney Research Institute, West China Hospital of Sichuan UniversityChengduChina
| | - S.‐J. Gou
- Division of NephrologyKidney Research Institute, West China Hospital of Sichuan UniversityChengduChina
| | - H.‐Y. Qiu
- Division of NephrologyKidney Research Institute, West China Hospital of Sichuan UniversityChengduChina
| | - L. Ma
- Division of NephrologyKidney Research Institute, West China Hospital of Sichuan UniversityChengduChina
| | - P. Fu
- Division of NephrologyKidney Research Institute, West China Hospital of Sichuan UniversityChengduChina
| |
Collapse
|
36
|
Fu P, Xiang X, Ge Y, Yuan Z, Hu X. Differential expression of duplicated binary toxin genesbinA/binBinLysinibacillus sphaericusC3-41. Lett Appl Microbiol 2017; 65:90-97. [DOI: 10.1111/lam.12752] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 04/25/2017] [Accepted: 04/26/2017] [Indexed: 11/28/2022]
Affiliation(s)
- P. Fu
- Wuhan Institute of Virology; Chinese Academy of Sciences; Wuhan China
- University of Chinese Academy of Sciences; Beijing China
| | - X. Xiang
- Wuhan Institute of Virology; Chinese Academy of Sciences; Wuhan China
| | - Y. Ge
- Wuhan Institute of Virology; Chinese Academy of Sciences; Wuhan China
| | - Z. Yuan
- Wuhan Institute of Virology; Chinese Academy of Sciences; Wuhan China
| | - X. Hu
- Wuhan Institute of Virology; Chinese Academy of Sciences; Wuhan China
| |
Collapse
|
37
|
Fu P, Gao G, Song ZQ, He SY, Qin PJ, Li D, Tang LJ, Wang WLS, Wu YB, Liang XY. Design and Test Results for the PF Power Supply System of EAST. Fusion Science and Technology 2017. [DOI: 10.13182/fst08-a1916] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- P. Fu
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - G. Gao
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - Z. Q. Song
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - S. Y. He
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - P. J. Qin
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - D. Li
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - L. J. Tang
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - W. L. S. Wang
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - Y. B. Wu
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| | - X. Y. Liang
- Chinese Academy of Sciences Institute of Plasma of Physics, Shushan Hu Road 350, Heifei, Anhui, China P.O. Box 1126, Heifei, Anhui, China 230031
| |
Collapse
|
38
|
Fu P, Liu ZZ, Xu JZ, Gao G, Wen JL, Cao Y, Song ZQ, Tang LJ, Wang LS, Liang XY. Poloidal Field Power Supply Systems for the HT-7U Steady-State Superconducting Tokamak. Fusion Science and Technology 2017. [DOI: 10.13182/fst02-a223] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- P. Fu
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - Z. Z. Liu
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - J. Z. Xu
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - G. Gao
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - J. L. Wen
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - Y. Cao
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - Z. Q. Song
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - L. J. Tang
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - L. S. Wang
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| | - X. Y. Liang
- Institute of Plasma Physics, Chinese Academy of Science, Box 1126, Hefei 230031, China
| |
Collapse
|
39
|
Fu P, Weyker PD, Webb CAJ. Case Report of Serratus Plane Catheter for Pain Management in a Patient With Multiple Rib Fractures and an Inferior Scapular Fracture. ACTA ACUST UNITED AC 2017; 8:132-135. [PMID: 28291768 DOI: 10.1213/xaa.0000000000000431] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We placed a superficial serratus anterior plane catheter in an elderly woman with dementia and elevated clotting times who presented with multiple rib fractures after a mechanical fall. She was not a surgical candidate, and treatment consisted of conservative management with physical therapy and pain control. She was not a candidate for a patient-controlled analgesia regimen because of her dementia. Given her elevated international normalized ratio, thoracic epidural and paravertebral analgesia was also contraindicated. We placed an ultrasound-guided serratus anterior plane catheter, allowing titratable continuous infusion in a trauma patient, resulting in excellent analgesia without adverse effects.
Collapse
Affiliation(s)
- Peter Fu
- From the *Department of Anesthesiology, Columbia University College of Physicians and Surgeons, New York, New York; †Department of Anesthesiology, Divisions of Pain Medicine and Critical Care, Columbia University Medical Center, New York, New York; and ‡Staff Anesthesiologist at Kaiser Permanente in San Francisco, California; Clinical Instructor in Anesthesiology, Perioperative & Pain Medicine, Stanford University School of Medicine, Stanford, California
| | | | | |
Collapse
|
40
|
Fu P, Gao G, Song ZQ, Xu LW, Huang LS, Jiang L, Li JC, Zha FW, Dong L, Wang M. Preliminary Design of the Poloidal Field AC/DC Converter System for the ITER Coil Power Supply. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a24094] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- P. Fu
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - G. Gao
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - Z.H. Q. Song
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - L. W. Xu
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - L. S. Huang
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - L. Jiang
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - J. C. Li
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - F. W. Zha
- Institute of Plasma Physics, Chinese Academy of Sciences (ASIPP), Hefei 230031, China
| | - L. Dong
- China International Nuclear Fusion Energy Program Execution Center, Beijing 100862, China
| | - M. Wang
- China International Nuclear Fusion Energy Program Execution Center, Beijing 100862, China
| |
Collapse
|
41
|
Baar J, Abraham J, Silverman P, Budd GT, Vinayak S, Varadan V, Moore H, Montero A, Fu P. Abstract OT2-01-10: Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-01-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND. Triple-negative breast cancer (TNBC) is associated with an aggressive phenotype and decreased survival. TNBC is characterized by tumor-infiltrating lymphocytes (TIL) which predict for a better prognosis and likely reflect immune recognition of tumor-associated antigens by TIL. However, potent immune suppressive signals exist in the tumor microenvironment such as those mediated by PD-1 with its ligand, PD-L1. Therefore, to test the validity of decreasing PD-1/PD-L1-mediated immune suppression, a Phase Ib study of single-agent pembrolizumab in 32 patients with advanced TNBC showed a partial response of 16.1% and stable disease of 9.7%, thereby attesting to the effectiveness of single-agent pembrolizumab in these patients. Other studies have demonstrated that cytotoxic chemotherapy favorably modulates immunity against cancer and there is therefore a strong rationale to combine chemotherapy with an immune modulator such as pembrolizumab for the treatment of mTNBC.
TRIAL DESIGN. This is an investigator-initiated, industry-sponsored (Merck) pilot study of carboplatin (C), nab-paclitaxel (N) and pembrolizumab (P) in 30 patients with metastatic (m) TNBC. Eligible patients will receive 3 cycles of CNP, with each cycle consisting of C (AUC 6 on days 1 of a 21-day cycle), N (100 mg/m2 IV on days 1, 8 and 15 of a 21-day cycle), and P (200 mg IV on day 15 of each cycle). After completion of 3 cycles CNP, patients with responding or stable disease by RECIST 1.1 criteria will be eligible for additional cycle(s) of CNP.
ELIGIBILITY CRITERIA. Patients must have radiologically measurable mTNBC, an ECOG performance status of 0-1, must not have received more than 2 prior therapies for this disease, and must be willing to undergo a preliminary biopsy of a metastatic focus for research purposes. A second post-treatment biopsy will be encouraged but will not be mandated.
SPECIFIC AIMS. The primary objective is to determine overall response rate (ORR) in patients treated with CNP. The secondary objectives are to determine progression-free survival (PFS) and safety/tolerability of CNP. Correlative objectives include the identification of pathologic and genomic correlates of response to CNP.
STATISTICAL METHODS. Clinical response will be scored using RECIST 1.1 criteria. Under the proposed treatment, the expected clinical response is about 35%. With the precision of the 2-sided 95% confidence interval for the response rate set to 0.17 (the distance to the expected response rate of 35%), the sample size required for the study is 30 patients. The true response rate of therapy will be estimated based on the number of responses using a binomial distribution and its confidence intervals will be estimated using Wilson's method. The Kaplan-Meier method will be used to estimate PFS. Factors including pathologic and genomic correlates that predict survival outcomes will be identified by Cox model or extensions of the Cox model.
TARGET ACCRUAL. We plan to enroll 30 patients over 2 years, with the first patient expected to be enrolled in September 2016.
CONTACT INFORMATION. Joseph Baar, MD, PhD. Seidman Cancer Center of University Hospitals Case Medical Center. E-mail: joseph.baar@uhhospitals.org.
Citation Format: Baar J, Abraham J, Silverman P, Budd GT, Vinayak S, Varadan V, Moore H, Montero A, Fu P. Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-01-10.
Collapse
Affiliation(s)
- J Baar
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - J Abraham
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - P Silverman
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - GT Budd
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - S Vinayak
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - V Varadan
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - H Moore
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - A Montero
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| | - P Fu
- Seidman Cancer Center, Cleveland, OH; Taussig Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
| |
Collapse
|
42
|
Fredman E, Tabayoyong W, Ponsky L, Abouassaly R, Traughber B, Fu P, Park S, Zhang Y, Podder T, Dobbins D, Ferry E, Patel D, Minnillo B, Smigelski M, Gonzalez C, Machtay M, Lo S, Ellis R. Stereotactic Body Radiation Therapy for Low-Intermediate Risk Prostate Cancer—A Single-Institution Initial Analysis of Toxicity. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Sun Y, Liang Y, Liu YQ, Gu S, Yang X, Guo W, Shi T, Jia M, Wang L, Lyu B, Zhou C, Liu A, Zang Q, Liu H, Chu N, Wang HH, Zhang T, Qian J, Xu L, He K, Chen D, Shen B, Gong X, Ji X, Wang S, Qi M, Song Y, Yuan Q, Sheng Z, Gao G, Fu P, Wan B. Nonlinear Transition from Mitigation to Suppression of the Edge Localized Mode with Resonant Magnetic Perturbations in the EAST Tokamak. Phys Rev Lett 2016; 117:115001. [PMID: 27661697 DOI: 10.1103/physrevlett.117.115001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Indexed: 06/06/2023]
Abstract
Evidence of a nonlinear transition from mitigation to suppression of the edge localized mode (ELM) by using resonant magnetic perturbations (RMPs) in the EAST tokamak is presented. This is the first demonstration of ELM suppression with RMPs in slowly rotating plasmas with dominant radio-frequency wave heating. Changes of edge magnetic topology after the transition are indicated by a gradual phase shift in the plasma response field from a linear magneto hydro dynamics modeling result to a vacuum one and a sudden increase of three-dimensional particle flux to the divertor. The transition threshold depends on the spectrum of RMPs and plasma rotation as well as perturbation amplitude. This means that edge topological changes resulting from nonlinear plasma response plays a key role in the suppression of ELM with RMPs.
Collapse
Affiliation(s)
- Y Sun
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - Y Liang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
- Institute for Energy and Climate Research-Plasma Physics, Forschungszentrum Jülich, 52425 Jülich, Germany
| | - Y Q Liu
- CCFE Culham Science Centre, Abingdon, OX14 3DB, United Kingdom
| | - S Gu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - X Yang
- School of Physics and Optoelectronic Engineering, Dalian University of Technology, Dalian 116024, China
| | - W Guo
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - T Shi
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - M Jia
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - L Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - B Lyu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - C Zhou
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - A Liu
- Department of Modern Physics, University of Science and Technology of China, Hefei 230026, China
| | - Q Zang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - H Liu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - N Chu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - H H Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - T Zhang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - J Qian
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - L Xu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - K He
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - D Chen
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - B Shen
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - X Gong
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - X Ji
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - S Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - M Qi
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - Y Song
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - Q Yuan
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - Z Sheng
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - G Gao
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - P Fu
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| | - B Wan
- Institute of Plasma Physics, Chinese Academy of Sciences, PO Box 1126, Hefei 230031, China
| |
Collapse
|
44
|
Chen Z, Yin C, Wang S, Fu QM, Deng QR, Lin ZD, Fu P, Zhang Y, Wu JY, Fang PF. The rheological behavior of ethylene vinyl acetate copolymer/rectorite nanocomposites during the melt extrusion process. POLYM ADVAN TECHNOL 2016. [DOI: 10.1002/pat.3813] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Z. Chen
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials; Wuhan Institute of Technology; Wuhan 430073 China
- Department of Material Science and Engineering; Wuhan Institute of Technology; Wuhan 430073 China
| | - C. Yin
- Department of Material Science and Engineering; Wuhan Institute of Technology; Wuhan 430073 China
| | - S. Wang
- Department of Material Science and Engineering; Wuhan Institute of Technology; Wuhan 430073 China
| | - Q. M. Fu
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials; Wuhan Institute of Technology; Wuhan 430073 China
| | - Q. R. Deng
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials; Wuhan Institute of Technology; Wuhan 430073 China
| | - Z. D. Lin
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials; Wuhan Institute of Technology; Wuhan 430073 China
| | - P. Fu
- Hubei Key Laboratory of Plasma Chemistry and Advanced Materials; Wuhan Institute of Technology; Wuhan 430073 China
| | - Y. Zhang
- Department of Material Science and Engineering; Wuhan Institute of Technology; Wuhan 430073 China
| | - J. Y. Wu
- Department of Material Science and Engineering; Wuhan Institute of Technology; Wuhan 430073 China
| | - P. F. Fang
- Department of Physics; Wuhan University; Wuhan 430072 China
| |
Collapse
|
45
|
Dowlati A, Lipka MB, McColl K, Dabir S, Behtaj M, Kresak A, Miron A, Yang M, Sharma N, Fu P, Wildey G. Clinical correlation of extensive-stage small-cell lung cancer genomics. Ann Oncol 2016; 27:642-7. [PMID: 26802149 PMCID: PMC4803453 DOI: 10.1093/annonc/mdw005] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 12/22/2015] [Accepted: 12/22/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Genomic studies in small-cell lung cancer (SCLC) lag far behind those carried out in nonsmall-cell lung cancer (NSCLC). To date, most SCLC studies have evaluated patients with surgically resectable disease. Here we sought to evaluate the genomic mutation spectrum of 'every-day' SCLC patient tumors with extensive stage disease (ES-SCLC) and to correlate mutations with the main clinical outcomes of response to chemotherapy, progression-free (PFS) and overall (OS) survival. PATIENTS AND METHODS A total of 50 SCLC patient tumors were examined in this study; targeted exome sequencing was obtained on 42 patients and whole-exome sequencing on 8 patients. Mutated genes were correlated with clinical outcomes using Kaplan-Meier methods (PFS, OS) and logistic regression (chemo-response). RB1 protein expression was detected by either western blotting of cultured cell lysates or immunohistochemistry of tumor specimens. RESULTS In all, 39 patients had ES-SCLC; 15 patients had either primary refractory/resistant disease and 21 patients had sensitive disease. The two most frequently mutated genes were TP53 (86%) and RB1 (58%); other frequently mutated genes (>10% patients) were involved in epigenetic regulation as well as the mTOR pathway. We identified a number of low-frequency, targetable mutations, including RICTOR, FGFR1, KIT, PTCH1 and RET. Using multivariate analysis, RB1 was the only significant factor (P = 0.038) in predicting response to first-line chemotherapy, with an odds ratio of 5.58 comparing mutant RB1 with wild-type. Patients with mutant RB1 had both better OS (11.7 versus 9.1 months P = 0.04) and PFS (11.2 versus 8.6 months, P = 0.06) compared with patients with wild-type RB1. Interestingly, ∼25% of SCLC cell lines and tumor specimens expressed RB1 protein, possibly representing the subgroup with wild-type RB1. CONCLUSIONS We found that SCLC tumors harboring no mutation in RB1 had a poor response to chemotherapy.
Collapse
Affiliation(s)
| | | | - K McColl
- Division of Hematology and Oncology
| | - S Dabir
- Division of Hematology and Oncology
| | - M Behtaj
- Division of Hematology and Oncology
| | - A Kresak
- Division of Pathology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland
| | - A Miron
- Department of Genetics and Genomic Sciences
| | - M Yang
- Division of Pathology, Case Western Reserve University and University Hospitals Seidman Cancer Center, Cleveland
| | - N Sharma
- Division of Hematology and Oncology
| | - P Fu
- Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, USA
| | - G Wildey
- Division of Hematology and Oncology
| |
Collapse
|
46
|
Fu P, Usatyuk PV, Ebenezer DL, Natarajan V. ID: 111: THE S1P TRANSPORTER, SPNS2, MEDIATES HGF-INDUCED LAMELLIPODIA FORMATION AND MIGRATION OF HUMAN LUNG ENDOTHELIAL CELLS. J Investig Med 2016. [DOI: 10.1136/jim-2016-000120.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
RationaleWe have demonstrated earlier that HGF-induced lamellipodia formation in human lung microvascular endothelial cells (HLMVECs) was through c-Met receptor tyrosine kinase and PI3 kinase/Akt signal transduction. Here, we show that HGF-mediated lamellipodia formation is dependent on intracellular S1P generation mediated by sphingosine kinase 1 (SphK1), the S1P transporter, Spns2 and S1P1 in HLMVECs.MethodsHLMVECs were treated with HGF (20 ng/ml) for different time points. Lamellipodia were detected after HGF treatment by immunofluorescent staining of Spns2, cortactin and actin in lamellipodia, and lamellipodia were quantified by measuring cell periphery fluorescence intensity. Pearson's correlation coefficient was used to statistically quantify co-localization of proteins in lamellipodia. Endogenous SphK activity was blocked by SphK1 specific inhibitor PF-543, and expression of SphK1 in cells was down-regulated by siRNA. Cellular S1P levels were quantified by mass spectrometry.ResultsHGF stimulated phosphorylation of SphK1, and its localization to lamellipodia of HLMVECs. Down-regulation of SphK1, but not SphK2, with siRNA or inhibition of SphK1 with PF-543 (1–5 µM) attenuated HGF-induced lamellipodia formation in HLMVECs. The HGF-mediated phosphorylation of SphK1 and its localization in lamellipodia was dependent on PI3K/Akt and ERK1/2 signaling apthways. HGF increased S1P levels in HLMVECs, which was blocked by inhibition of SphK1 with PF-543. Further, HGF induced serine phosphorylation and translocation of Spns2, the S1P transporter, to lamellipodia, which was Akt dependent. The HGF-induced lamellipodia formation in HLMVECs was blocked by down-regulation of Spns2, suggesting extracellular action of S1P in lamellipodia formation. Down-regulation of S1P1, but not S1P2 or S1P3, with siRNA attenuated HGF-induced lamellipodia formation. Further, HGF stimulation enhanced association of Spns2 with S1P1 and blocking SphK1 activty with PF-543 attenuated the association between Spns2 and S1P1. Additionally, HGF-induced migration of HLMVECs was attenuated by down-regulation of Spns2.ConclusionThese results suggest that HGF/c-Met mediated lamellipodia formation and motility is dependent on intracellular generation of S1P via activation and localization of SphK1 to cell periphery and Spns2 mediated transport of S1P to outside for signaling via S1P1 in HLMVECs. This work was supported by NIH/HLBI P01 HL98050 to VN.
Collapse
|
47
|
Shaaya M, Fu P, Karginov A, Natarajan V. ID: 120: REGULATION OF ENDOTHELIAL BARRIER PERMEABILITY BY PHOSPHOLIPASE D2. J Investig Med 2016. [DOI: 10.1136/jim-2016-000120.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Pulmonary edema is a hallmark of several diseases including acute respiratory distress syndrome (ARDS) and is characterized by the disruption of the pulmonary endothelial barrier at its early stage. Maintaining the integrity of the adherens junctions (AJs) by stabilizing VE-Cadherin (VEC) at the cell membrane after injury could potentially be important to minimize endothelial barrier disruption. Since Phospholipase D (PLD) and its catalytic product, phosphatidic acid (PA), has been shown to be critical in membrane trafficking and in recycling of a number of cell surface receptors, we hypothesized that PLD/PA pathway accelerates the rate of VEC recycling to the lamellipodia to reassemble the AJs. We demonstrate, by measuring the trans endothelial resistance of human lung microvascular endothelial cells (HLMVECs), that inhibiting PLD2-dependent PA production increases the endothelium permeability in response to thrombin. Furthermore, immunostaining shows that the uniform redistribution of VEC to the AJs post thrombin insult is compromised when PLD-dependent PA production is inhibited, and resulted in the appearance of eminent intercellular gaps. Also, PLD2 inhibition prevented the HLMVECs from fully spreading after thrombin stimulation while the protrusive activity remained unaffected, suggesting that PLD2 is not required by HLMVECs to send protrusions, but is critical for the adherence of the protrusions. LPS-induced lung injury was more severe in PLD2 knockout mice compared to WT in an in vivo ARDS model. These observations suggest that PLD/PA signaling plays an important role in resealing of endothelial gaps post LPS-induced lung injury and could potentially be therapeutically utilized to enhance post-injury endothelium recovery.
Collapse
|
48
|
Baar J, Storkus W, Finke J, Butterfield L, Lazarus H, Reese J, Brufsky A, Downes K, Budd GT, Fu P. Abstract OT1-01-02: Pilot trial of a type I polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot1-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND. Cancer vaccines based on tumor-associated antigens are rarely curative in advanced cancer. This limitation relates to the heterogeneity of cancer due to defects in antigen presentation and altered immunophenotypes. Therefore, another method to promote anti-tumor immunity is to prime T cells against tumor-associated stromal cells. We have reported that IL-12 gene-therapy of established HLA-A2neg B16 melanomas in HLA-A2 transgenic (Tg) mice resulted in CD8+ T cell-mediated immunity against the host HLA-A2+ stromal cells within the tumor microenvironment (TME). We have also shown that vaccines based on a subset of tumor blood vessel antigen (TBVA)-derived peptides (DLK1310-318, EphA2883-891, HBB31-39, NRP1433-441, RGS55-13 and TEM1691-700) prevented HLA-A2neg MC38 tumor establishment and promoted the regression of melanomas in HLA-A2 Tg mice by CD8+ T cell targeting of HLA-A2+ pericytes and vascular endothelial cells in the TME.
TRIAL DESIGN. Based on this pre-clinical data, we are undertaking a Susan G. Komen-funded (IIR13261822; IND 15722) IRB-approved clinical trial of chemo-immunotherapy using the immunomodulatory drug gemcitabine (GEM) to suppress tumor infiltrating suppressor cells such as myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs) with a dendritic cell (DC) vaccine pulsed with the above six HLA-A2-presented TBVA-derived peptides (DC-TBVA) in 30 HLA-A2+ patients with metastatic breast cancer (MBC). Eligible patients will first undergo leukapheresis for the generation of the DC-TBVA vaccine. Patients will then receive 3 cycles of GEM, 1000 mg/m2 IV on days 1 and 8 of a 21-day cycle for 3 cycles. Patients will then receive the DC-TBVA vaccine administered twice intradermally 7 days apart.
ELIGIBILITY CRITERIA. Patients must be HLA-A2+ and have radiologically measurable MBC, an ECOG performance status of 0-1 and not have any active immune disorders. Prior GEM therapy is acceptable as long as the last dose was ≥ 3 months from registration on this study. Patients may not be on steroids.
SPECIFIC AIMS. The 4 specific aims are to 1) assess the safety of GEM + αDC1-TBVA vaccination, 2) assess the clinical response of MBC to GEM + αDC1-TBVA vaccination, 3) determine the clinical efficacy of GEM + αDC1-TBVA vaccination in generating Tc1 immunity, and 4) correlate changes in MDSC and Tregs with the generation of anti-TBVA Tc1-cell immunity
STATISTICAL METHODS. Clinical response: if the response rate is less than 10%, then there is probability 0.05 or less of accepting the vaccine therapy; if the response rate is bigger than 32%, then the probability of rejecting the combination is less than 0.2. While the secondary goals of the study are exploratory, there is sufficient statistical power to identify moderate to large effects (i.e., there will be statistical power >.80 to detect changes from baseline in the different immune function parameters that are >0.6 standard deviations of the parameter.)
TARGET ACCRUAL. We will enroll 30 patients over 3 years, with the first patient expected to be enrolled in July 2015.
CONTACT INFORMATION. Joseph Baar, MD, PhD. Seidman Cancer Center. E-mail: joseph.baar@uhhospitals.org.
Citation Format: Baar J, Storkus W, Finke J, Butterfield L, Lazarus H, Reese J, Brufsky A, Downes K, Budd GT, Fu P. Pilot trial of a type I polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT1-01-02.
Collapse
Affiliation(s)
- J Baar
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - W Storkus
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - J Finke
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - L Butterfield
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - H Lazarus
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - J Reese
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - A Brufsky
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - K Downes
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - GT Budd
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| | - P Fu
- Case Comprehensive Cancer Center - Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center - Taussig Cancer Center, Cleveland, OH; University of Pittsburgh Medical Center, Pittsburgh, PA
| |
Collapse
|
49
|
Lu C, Li L, Luo Z, Cui Y, Fu P, Zhou J, Ma N, Zhou Y. Clinical efficacy of type-B ultrasound-guided intraperitoneal hyperthermic chemoperfusion combined with systemic chemotherapy in advanced gastric cancer patients with malignant ascites. Neoplasma 2016; 63:299-303. [PMID: 26774152 DOI: 10.4149/217_150622n345] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVES To evaluate the clinical efficacy of systemic chemotherapy combined with intraperitoneal hyperthermic perfusion in advanced gastric cancer patients with malignant ascites. PATIENTS AND METHODS Forty-eight gastric cancer patients with malignant ascites who were admitted to our hospital were selected and randomly divided into the hyperthermic perfusion and control groups. The control group only received systemic chemotherapy, and the hyperthermic perfusion group received systemic chemotherapy combined with intraperitoneal hyperthermic chemoperfusion. The therapeutic efficacy, the survival time and the associated toxicity were determined for the two groups. RESULTS The efficacy was significantly higher in the hyperthermic perfusion group (85.7%) than in the control group (30.0%) (P 0.05). The median progression-free survival (PFS) was significantly longer in the hyperthermic perfusion group (12 months) compared with the control group (6 months) (P < 0.05). The median overall survival (OS) was significantly longer in the hyperthermic perfusion group (21 months) compared with the control group (9 months) (P < 0.05). There was a significantly higher 1-year survival rate in the hyperthermic perfusion group (89.3%) than in the control group (36.4%) (P < 0.05); however, there was no significant difference in the 3-year survival rate (10.7% vs. 10.0%). The Karnofsky Performance Status (KPS) score in the hyperthermic perfusion group increased significantly from 62.8 ± 1.84 to 74.3 ± 5.0 after hyperthermic chemoperfusion (P < 0.05). CONCLUSION Systemic chemotherapy combined with intraperitoneal hyperthermic perfusion exhibited significant clinical efficacy in advanced gastric cancer patients with malignant ascites, helped control ascites, improved the quality of life and extended PFS and OS. This treatment regimen is worth promoting.
Collapse
|
50
|
Fu P, Du F, Liu Y, Hong Y, Yao M, Zheng S. Wogonin increases doxorubicin sensitivity by down-regulation of IGF-1R/AKT signaling pathway in human breast cancer. Cell Mol Biol (Noisy-le-grand) 2015; 61:123-127. [PMID: 26638893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 11/26/2015] [Indexed: 06/05/2023]
Abstract
Currently drug resistance has remained a major challenge in successful breast cancer therapy. Wogonin, one of the active components of scutellaria baicalensis, has shown anticarcinogenic, chemopreventive, and immunoregulatory functions. The present study aimed to explore whether wogonin exerted synergistic cytotoxicity with doxorubicin in breast cancer. Our data indicated that wogonin inhibited the proliferation of breast cancer cells in a dose- and time-dependent manner. Combined treatment with wogonin increased the doxorubicin sensitivity in breast cancer cells. Moreover, administration with wogonin alone or in combination with doxorubicin suppressed the expression of insulin like growth factor 1 receptor (IGF-1R) in Bcap-37 and MCF-7 cells. Incubation with insulin like growth factor (IGF) I or IGF-II promoted cell growth, which was reversed by wogonin co-administration. Mechanically, we found that down-regulation of IGF-1R diminished the chemosensitization role of wogonin in breast cancer. In addition, wogonin suppressed the phosphorylation levels of AKT and addition of AKT inhibitor abolished the synergistic cytotoxicity of wogonin and doxorubicin. Taken together, combined treatment with wogonin increased the doxorubicin sensitivity in breast cancer cells through regulation of IGF-1R/AKT signaling pathway. Therefore, these findings demonstrated that combination therapy with wogonin led to better therapeutic effects via regulating IGF-1R/AKT signaling pathway in doxorubicin-based chemotherapy for breast cancer.
Collapse
Affiliation(s)
- P Fu
- The First Affiliated Hospital, School of Medicine, Zhejiang University Department of General Surgery Hangzhou China
| | - F Du
- First Affiliated Hospital, School of Medicine, Zhejiang University Department of Orthopaedics Hangzhou China
| | - Y Liu
- The First Affiliated Hospital, School of Medicine, Zhejiang University Department of General Surgery Hangzhou China
| | - Y Hong
- The First Affiliated Hospital, School of Medicine, Zhejiang University Department of General Surgery Hangzhou China
| | - M Yao
- The First Affiliated Hospital, School of Medicine, Zhejiang University Department of General Surgery Hangzhou China
| | - S Zheng
- The First Affiliated Hospital, School of Medicine, Zhejiang University Department of General Surgery Hangzhou China
| |
Collapse
|